Seattle Genetics signs $4.4bn worth oncology deals with Merck

US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major pharma companies will develop and commercialize Seattle Genetics’ ladiratuzumab vedotin across the world. Ladiratuzumab vedotin is an investigational antibody-drug conjugate (ADC) that targets More...

by pharmanewsdaily | Published 1 week ago
By pharmanewsdaily On Monday, September 14th, 2020
0 Comments

Gilead acquisition of Immunomedics : Pharma giant to gain access to breast cancer drug Trodelvy

Gilead acquisition of Immunomedics : US pharma giant Gilead Sciences has signed a $21 billion worth deal to acquire New Jersey-based biopharma company Immunomedics to gain access to the latter’s FDA approved More...

By pharmanewsdaily On Saturday, September 12th, 2020
0 Comments

Gan & Lee gets FDA orphan drug status for GLR2007 in malignant glioma

Gan & Lee Pharmaceuticals has been given orphan drug designation from the US Food and Drug Administration (FDA) for GLR2007 for the treatment of malignant glioma, an aggressive primary brain tumor. According More...

By pharmanewsdaily On Saturday, September 12th, 2020
0 Comments

Reyvow CENTURION trial results : Lilly migraine drug succeeds in phase 3 study

Reyvow CENTURION trial results : Eli Lilly and Company (Lilly) said that its migraine drug Reyvow (lasmiditan) has met the co-primary endpoint of a phase 3 clinical trial called CENTURION by delivering pain freedom More...

By pharmanewsdaily On Saturday, September 12th, 2020
0 Comments

SK Biopharmaceuticals launches phase 3 trial of seizures drug cenobamate in Asia

SK Biopharmaceuticals, a South Korean pharma company, has revealed plans to initiate a phase 3 clinical trial for its FDA-approved seizures drug cenobamate in Asia. Cenobamate was approved by the US Food and Drug More...

By pharmanewsdaily On Saturday, September 12th, 2020
0 Comments

Bruker acquires Missouri-based life science company Canopy Biosciences

US scientific instruments manufacturer Bruker Corporation has acquired Canopy Biosciences, a life science company engaged in providing high multiplex biomarker imaging for immunology, immuno-oncology, and cell therapy, More...

By pharmanewsdaily On Saturday, September 12th, 2020
0 Comments

United Therapeutics appoints Dr Linda Maxwell to board of directors

United Therapeutics, a Maryland biotech company, has appointed head and neck surgeon Dr Linda Maxwell to its board of directors as an independent director. Dr Linda Maxwell is also a medical educator, a health technology More...

By pharmanewsdaily On Friday, September 11th, 2020
0 Comments

Takeda’s NINLARO fails to meet PFS primary endpoint in TOURMALINE-MM2 trial

Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib) in addition to lenalidomide and dexamethasone failed to meet the primary endpoint More...

By pharmanewsdaily On Thursday, September 10th, 2020
0 Comments

KA Imaging gets FDA clearance for Reveal X-ray detector

KA Imaging said that Reveal, its portable dual-energy X-ray detector has been granted 510(k) clearance from the US Food and Drug Administration (FDA). The Canadian X-ray detector manufacturer said that Reveal enables More...

By pharmanewsdaily On Thursday, September 10th, 2020
0 Comments

Evonetix, Analog Devices join forces for third gen DNA synthesis platform

Evonetix, a synthetic biology company, which is engaged in developing a desktop platform for rapid gene synthesis, has entered into a collaboration to develop a third-generation DNA synthesis platform with Analog More...